Serum macrophage migration‐inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer

作者：Harry Hua‐Xiang Xia, Yi Yang, Kent‐Man Chu, Qing Gu, Yuanyuan Zhang, Hua He, Wai Man Wong, Suet‐Yi Leung, Siu–Tsan Yuen, Man‐Fung Yuen, Annie O.O. Chan, Benjamin C.Y. Wong · 发表于：Cancer · 年份：2009 · DOI：10.1002/cncr.24609 · 被引用次数：60 · 研究领域：Macrophage Migration Inhibitory Factor、Inflammation biomarkers and pathways、Signaling Pathways in Disease

BACKGROUND: This study aimed to determine the potential diagnostic value of migration-inhibitory factor (MIF) for gastric cancer in patients presenting with dyspepsia and its prognostic value for gastric cancer. METHODS: A cohort of 97 patients with histologically confirmed gastric adenocarcinoma and 222 patients with dyspepsia were recruited. Enzyme-linked immunosorbent assay was used to measure serum MIF and carcinoembryonic antigen (CEA). RESULTS: The serum MIF concentrations were 6554.0 +/- 204.1 pg/mL and 1453.7 +/- 79.9 pg/mL, respectively, in gastric cancer patients and dyspeptic patients (P < .001). Serum MIF levels increased with the advancing gastric pathologies (P < .001). With the cutoff value of 3230 pg/mL, serum MIF had sensitivity, specificity, and accuracy of 83.5%, 92.3%, and 89.7%, respectively, in diagnosing gastric cancer, whereas the rates were 60.8%, 83.3%, and 76.5%, respectively, for serum CEA. Gastric cancer patients with serum MIF levels above 6600 pg/mL had a lower 5-year survival rate than those with serum MIF level below that level (P = .012). Higher serum CEA levels were also associated with poor survival. The prediction for 5-year survival was even better (P = .0001), using a combination of serum MIF and CEA. CONCLUSIONS: Serum MIF level, which correlates with gastric MIF expression, is a better molecular marker than CEA in diagnosing gastric cancer in patients presenting with dyspepsia. A combination of serum MIF and CEA predicts 5-year surviva...